← Back to Search

Virus Therapy

ABA-101 for Multiple Sclerosis

Phase 1
Recruiting
Research Sponsored by Abata Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Is ≥18 years old at signing of consent
Has documented evidence of progression of disability independent of MS relapse activity (clinical or radiographic)
Must not have
Current treatment with disease-modifying therapies (DMTs)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day of treatment to end of dlt evaluation period (28 days)
Awards & highlights
No Placebo-Only Group

Summary

This trial will test the safety and effects of a new treatment, ABA-101, on people with progressive multiple sclerosis. It is the first time this treatment is being tested in humans. The study

Who is the study for?
This trial is for adults over 18 with progressive multiple sclerosis, confirmed by the McDonald criteria. Participants must show signs of brain inflammation on MRI, have worsening disability not linked to MS relapses, match a specific genetic marker (HLA), and meet certain physical function tests.
What is being tested?
The study is testing ABA-101's safety and effects in humans for the first time. It starts with a low dose to ensure safety before moving on to higher doses in participants with progressive MS.
What are the potential side effects?
Since this is the first human trial of ABA-101, exact side effects are unknown but will be closely monitored starting at lower doses to assess any potential risks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My MS is getting worse without having relapses.
Select...
My cancer cells match a specific immune system marker.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently on medication to slow my disease's progression.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day of treatment to end of dlt evaluation period (28 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and day of treatment to end of dlt evaluation period (28 days) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of adverse events (safety and tolerability)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: ABA-101 Dose 2Experimental Treatment1 Intervention
High Dose ABA-101
Group II: ABA-101 Dose 1Experimental Treatment1 Intervention
Low Dose ABA-101

Find a Location

Who is running the clinical trial?

Abata TherapeuticsLead Sponsor
~8 spots leftby Feb 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top